Nexalin Technology, Inc. announced on October 28, 2024, the publication of a landmark study in the Journal of Alzheimer's Disease. The study, titled “Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Study,” highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease.
The research involved 46 patients, randomly assigned to receive either real Deep Intracranial Frequency Stimulation (DIFS) or sham treatment over three weeks. Resting-state functional magnetic resonance imaging (rs-fMRI) showed that Nexalin’s proprietary DIFS technology significantly alters neuronal activity in key brain regions, offering a non-pharmacological treatment option.
This study builds on previous DIFS research that demonstrated improvements in memory and cognitive function, including significant gains in MMSE and MoCA scores, and increased neural activity and blood flow in the hippocampus. The findings strengthen the case for non-invasive stimulation therapies like DIFS in addressing the root causes of cognitive decline in Alzheimer’s patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.